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Background and objectives: Alcohol use disorders (AUDs) are an important cause of 
morbidity and mortality. Despite the National Institute on Alcohol Abuse and Alcoholism 
(NIAAA) recommendations that medications be considered for patients with alcohol 
dependence, the mainstay of treatment has been counseling. We designed a survey 
to assess the treatment practices of psychiatrists and family medicine (FM) physicians 
in an effort to identify barriers to the use of pharmacotherapy and develop strategies to 
increase physician knowledge and utilization of these medications.
Methods: An anonymous online survey was sent to FM physicians and psychiatrists 
nationwide. The survey collected demographic information and assessed prescription 
of medications in treating AUDs, including FDA-approved medications and other medi-
cations used off-label for this purpose. We also examined factors that would lead to an 
increase in AUDs pharmacotherapy.
results: A total of 491 surveys were completed, with 475 responses included in the final 
analyses. 45.5% of participants were psychiatrists vs. 54.5% FM physicians. The 74.7% 
respondents had used medications to treat AUDs, with psychiatrists more likely to have 
prescribed acamprosate, naltrexone, and several off-label medications. FM physicians 
were more likely to report efficacy concerns. A majority of all physicians sampled would 
increase pharmacotherapy of AUDs with increased training.
Discussion: In our sample, most physicians have used medications to treat AUDs. 
There were concerns about efficacy with all non-FDA-approved medications, but limited 
treatment success even with FDA-approved medications. Greater education about 
pharmacotherapy, including predictors for treatment response amongst patients, should 
help alleviate some of the uncertainties reported with medications’ efficacy and lead to a 
more individualized treatment approach.
Keywords: alcohol use disorder, pharmacotherapy, family physicians, psychiatrists, survey
iNtrODUctiON
Alcohol-related problems are a vital cause of morbidity and mortality across the world. According 
to the World Health Organization (WHO), in 2012, about 3.3 million deaths, or 5.9% of all global 
deaths, were attributable to alcohol use (1). The 2014 National Survey on Drug Use and Health 
(NSDUH) revealed 23% of people ≥12 years old in the United States (60.9 million) and 6.2% of the 
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population in this age range (16.3 million) reported binge drink-
ing and heavy drinking in the previous 30 days, respectively (2).
Despite the high cost and prevalence of substance use disor-
ders (SUDs), they have historically been undertreated. In fact, 
according to the 2014 NSDUH, among the 22.5 million individu-
als older than 12 years who needed treatment for SUDs, only 2.6 
million received treatment at a specialty facility (2). Using data 
from the National Epidemiologic Survey on Alcohol and Related 
Conditions (NESARC), sponsored by the National Institute on 
Alcohol Abuse and Alcoholism (NIAAA) in the early 2000s, 
Hasin and colleagues found that only 24.1% of those with alcohol 
dependence were ever treated. When compared to treatment rates 
from data available 10 years earlier, this was actually a decline in 
treatment rate (3).
The mainstay of treatment for alcohol use disorders (AUDs) 
in the U.S. has generally been counseling or 12-step programs. 
Ducharme et  al. examined adoption of pharmacotherapy for 
alcohol dependence in specialty addiction treatment facilities 
during 1995–2004, finding that this practice was relatively 
uncommon (4). Federal data from substance abuse treatment 
facilities across the U.S. from 2013 reveal that only about 17–19% 
prescribed FDA-approved medications for AUDs treatment (5). 
Review of prescription practices among substance abuse special-
ists (6), substance abuse treatment facilities (4), Veterans Health 
Administration facilities (7, 8), and U.S. sales volume of prescrip-
tions (9) has corroborated these findings.
Since 2005, NIAAA has recommended that medications 
should be considered for every patient with alcohol dependence 
(10). There are currently four FDA-approved medications for the 
treatment of AUDs: disulfiram, naltrexone (oral and extended-
release injectable formulations), and acamprosate. Efficacy studies 
have supported the use of these medications in the treatment of 
AUDs, with results demonstrating mainly modest effects (11, 12). 
In a large utilization and cost study of alcohol pharmacotherapy, 
Baser et  al. found that patients who received medication had 
lower health-care utilization and total costs than patients who 
did not, despite the costs of these medications (13).
Primary care physicians and psychiatrists have potentially 
a greater vantage point for detection and perhaps intervention 
of AUDs. Primary care physicians often identify AUDs when 
evaluating patients for other medical reasons, while psychiatrists 
tend to have greater training in addictions and often deal with 
comorbid psychiatric and SUDs (14). Because prior studies have 
shown that use of medications for treatment of AUDs varies by 
medical specialty (6, 9, 14, 15), we designed a survey to assess 
the practices of the two specialties most likely to detect patients 
with AUDs, psychiatrists, and family medicine (FM) physicians. 
This was done in an effort to identify barriers to the use of phar-
macotherapy and develop strategies that would lead to greater 
physician knowledge and ultimately greater use of medications 
in the treatment of patients with these disorders.
MAteriALs AND MetHODs
Participants
Beginning in April 2012, we emailed an online survey designed 
using SurveyMonkey (https://www.surveymonkey.com), to FM 
physicians and Psychiatrists at all levels of training nationwide. 
Participants were recruited by contacting 52 chapters of the 
American Academy of Family Physicians, 70 chapters of the 
American Psychiatric Association, and ACGME-accredited 
psychiatry (183) and FM (455) residency programs in the United 
States. Invitations to participate were initially sent to the leaders 
of the specialty chapters, as well as program directors and/or coor-
dinators of the residency programs. They in turn distributed the 
survey invitation to their professional listservs and their faculty/
trainees, respectively. A second email was sent out to all initial 
contacts, except those who had declined participation, 7–10 days 
later, as a reminder to complete the survey. Prospective participants 
were informed that the study’s objective was to assess whether phy-
sicians have used medications in the treatment of AUDs and what 
their experiences have been with these medications. Participants 
were not compensated for completion of the survey, but were 
offered the option of entering their email addresses for a raffle of 
two prizes (an iPad or a 1-year paid membership to the American 
Society of Addiction Medicine). Responses were collected until 
mid-June 2012. The University of Virginia’s Institutional Review 
Board approved the research design.
Demographic Data
The survey asked physicians’ primary specialty, if they were spe-
cialized in addictions, their level of training, or number of years 
since completion of residency (current resident/fellow, completed 
residency within last 10 years, completed residency over 10 years 
ago), their state of practice, and their primary medical practice 
setting. Participants specializing in both FM and psychiatry as 
well as those identifying another primary specialization were 
excluded from this study.
survey tool
The online survey consisted of a total of 24 questions, includ-
ing demographic questions. Because “skip logic” was employed 
in some key questions, no participant completed all questions, 
based on their responses. The questions pertained to partici-
pants’ use of pharmacotherapy in the treatment of AUDs, their 
experiences with several medications, their level of training 
in pharmacotherapy for AUDs, and factors that would lead to 
increased prescription of medications in the treatment of AUDs. 
A definition of AUDs, per DSM-5, was provided. Participants 
were asked to exclude treatment for alcohol withdrawal in their 
responses. Survey completion time was about 5  min. All indi-
vidual responses were kept anonymous.
Pharmacotherapy in AUDs
The survey assessed whether participants had prescribed medica-
tions in the treatment of AUDs with a yes/no question, which 
was necessary for further completion of the survey. Because 
of “skip logic,” participants who selected “no” in this question 
did not complete the portion of the survey dedicated to evalu-
ation of specific medications. For those who selected “yes,” the 
medications prescribed were assessed via a multiple-choice 
question that included FDA-approved medications (disulfiram, 
naltrexone, and acamprosate) as well as several other “off-label” 
medications obtained from literature reviews – antidepressants, 
FiGUre 1 | Geographical distribution of participants. Survey participants’ geographical distribution by state is provided.
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carbamazepine, gabapentin, ondansetron, topiramate, and 
varenicline (6, 11, 12, 16, 17). A follow-up question asked which 
of the medications that had been prescribed produced favorable 
results.
To evaluate participants’ concerns with the prescription of 
specific medications, we created individual questions regarding 
naltrexone, disulfiram, acamprosate, topiramate, gabapentin, 
and varenicline. These included commonly cited reasons for not 
prescribing these medications, including cost, efficacy, tolerabil-
ity, and lack of experience with the medication, and poor patient 
compliance (6, 15).
Participants who indicated they do not prescribe medica-
tions in the treatment of AUDs were asked for their reasons in 
a separate multiple-choice question (i.e., “I do not have patients 
with alcohol use disorders,” “I prefer to only refer patients to 
Alcoholics Anonymous or other 12-step programs”).
statistical Analysis
Chi-square analyses were used to identify differences by speciali-
zation and training level for ever use of medications, medications 
having the best results, and reasons for not prescribing medica-
tions. Univariate analyses of prevalence ratio (PR) estimates of 
the ever use of these medications were evaluated by specialization 
and training level, followed by multivariate analyses adjusting 
for these two variables. Statistical analyses were performed with 
SAS™ (Version 9.4, SAS Institute, Inc., Cary, NC, USA).
resULts
A total of 491 surveys were completed between April and June 2012.
Demographics
Also, 45.5% of survey participants were identified as psychiatrists 
vs. 54.5% as FM. A minority of respondents had a subspecialty in 
addictions (9.9%). The level of training of participants was widely 
distributed, with 32.2% of participants currently in residency 
or fellowship training, 20% having completed residency within 
the previous 10  years, and 47.8% having completed residency 
>10  years prior. Geographical distribution of respondents is 
available in Figure 1.
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Pharmacotherapy
While nearly 75% of all participants have ever used medications 
in the treatment of AUDs, FM participants were less likely to have 
used pharmacotherapy (p <  0.001). After adjusting for level of 
training, psychiatrists were more likely to have ever prescribed 
the FDA-approved medications acamprosate (PR: 1.46, 95% CI: 
1.21–1.76, p < 0.001) and naltrexone (PR: 2.59, 95% CI: 2.07–3.23, 
p < 0.001), respectively (Table 1). Among medications without 
current FDA approval for treatment of alcohol dependence, psy-
chiatrists were more likely to have ever prescribed carbamazepine 
(PR: 2.25, 95% CI: 1.32–3.85, p = 0.003), gabapentin (PR: 2.84, 
95% CI: 1.86–4.34, p <  0.001), and topiramate (PR: 4.68, 95% 
CI: 2.73–8.01, p <  0.001). There was no statistical significance 
between psychiatry and FM in the prescription of antidepres-
sants, ondansetron, and varenicline.
There were differences in the ever use of medications to treat 
AUDs according to level of training. The differences in prescrip-
tion of acamprosate, disulfiram, naltrexone, and ondansetron were 
statistically significant across these groups (Table 1). Disulfiram, 
the first FDA-approved medication for treatment of alcohol 
dependence, was most frequently prescribed by physicians who 
completed training >10 years ago (n = 150, 80.2% of physicians in 
that level of training). When compared with current residents/fel-
lows, senior physicians were more likely to have ever prescribed 
acamprosate, disulfiram, and naltrexone (Table 1).
More than one-third of physicians who had prescribed one of 
the FDA-approved medications for treatment of AUDs had pre-
scribed at least one of the other FDA-approved medications. For 
example, 41.7% of physicians had prescribed both disulfiram and 
acamprosate, 40.0% had prescribed acamprosate and naltrexone, 
and 42.3% had prescribed disulfiram and naltrexone. Compared 
to FM, psychiatrists had the best results with naltrexone (47.5 
vs. 13.8%) and disulfiram (27.1 vs. 24.7%). FM physicians were 
more likely to select “none” as their medication of choice (33.9 
vs. 20.4%) and acamprosate (20.1 vs. 13.3%). Concerns regarding 
efficacy also appeared when analyzing the groups according to 
level of training; 31.6% of physicians who completed training 
>10 years ago had the best results with disulfiram, vs. 22.1% of 
physicians who completed training within 10  years and 17.6% 
of current residents or fellows (p  =  0.031). Physicians who 
completed residency within 10  years had the best results with 
acamprosate (28.6%), vs. 16.0% of more experienced physicians 
and 7.7% of current residents/fellows (p = 0.001).
Family medicine physicians were more likely than psychiatrists 
to identify reasons such as lack of training or experience (PR: 2. 4, 
95% CI: 1.58–3.65, p < 0.001), their preference to refer patients 
to Alcoholics Anonymous or another 12-step program (PR: 3.17, 
95% CI: 1.20–8.35, p =  0.020), and concerns about the cost of 
these medications (PR: 6.67, 95% CI: 1.55–28.70, p =  0.011). 
Among the physicians who had not prescribed medications in 
treating AUDs, the majority were FM physicians (75.3%), and 
most identified lack of training or experience with these medica-
tions as the number one obstacle (n = 85, 70.8%).
Promoting Use of Pharmacotherapy
A majority of all physicians sampled (87.6% of FM, 66.7% of 
psychiatrists) would increase their prescription of medications to 
treat AUDs if they had more training. FM physicians were more 
likely to use pharmacotherapy to treat AUDs if they had more 
time with their patients (PR: 2.29, 95% CI: 1.53–3.42, p < 0.001). 
Physicians’ preferred method of training was continuing medical 
education or Grand Rounds at their place of practice (n = 336, 
70.7%), online training modules (56.8%), reading materials via 
email or mail (48.4%), and live workshops (41.1%).
DiscUssiON
In our sample, use of FDA-approved medications for treatment 
of alcohol dependence was the most common amongst both 
specialties, and psychiatrists had a greater tendency to prescribe 
tABLe 1 | Adjusted prevalence ratio of ever use of medications.
Medication training level
Psychiatry vs. family medicinea experience level 2 vs. 1b experience level 3 vs. 1c
Adj prev ratio 95% ci p value Adj prev ratio 95% ci p value Adj prev ratio 95% ci p value
Acamprosate 1.46 1.21–1.76 <0.001 1.93 1.46–2.53 <0.001 1.46 1.10–1.93 0.009
Carbamazepine 2.25 1.32–3.85 0.003 1.80 0.92–3.55 0.088 1.31 0.70–2.47 0.397
Disulfiram 0.95 0.84–1.07 0.415 1.32 1.04–1.69 0.023 1.51 1.23–1.86 <0.001
Gabapentin 2.84 1.86–4.34 <0.001 1.22 0.81–1.83 0.336 0.77 0.52–1.15 0.202
Naltrexone 2.59 2.07–3.23 <0.001 1.80 1.40–2.31 <0.001 1.51 1.19–1.93 <0.001
Antidepressants (SSRIs/SNRIs) 1.13 0.92–1.39 0.255 1.06 0.81–1.38 0.678 0.86 0.67–1.09 0.215
Ondansetron 0.49 0.26–0.95 0.036 0.35 0.15–0.84 0.019 0.19 0.08–0.41 <0.001
Topiramate 4.68 2.73–8.01 <0.001 1.30 0.83–2.03 0.244 0.94 0.61–1.44 0.766
Varenicline 1.18 0.54–2.56 0.674 1.40 0.52–3.71 0.505 0.72 0.28–1.87 0.505
aReference group is family medicine.
bReference group is current residents/fellows when compared to those completing residency within 10 years.
cReference group is current residents/fellows when compared to those completing residency more than 10 years ago.
Level 1 = current resident/fellow.
Level 2 = completed residency ≤10 years ago.
Level 3 = completed residency >10 years ago.
Prevalence ratios are adjusted for specialization and level of training.
Red font highlights significant p Value.
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medications without FDA approval. However, FM physicians 
were more likely to report lack of results with the medication 
options offered. In general, both specialties had concerns about 
the efficacy of all non-FDA-approved medications, but even 
among FDA-approved medications, physicians reported limited 
success in treatment.
A large proportion of physicians in our sample reported using 
antidepressants as treatment for AUDs. However, the literature 
supports no such use for alcohol dependence (17), unless comor-
bidity with depression is taken into consideration.
There are several limitations to this study. First, due to the 
sampling methodology, we were unable to calculate a survey 
response rate despite a large response. However, our data show 
similar trends in the prescribing practices of these two specialties, 
as seen in previous surveys found in the literature (6, 9, 14, 15). 
Second, due to the convenience sampling methodology employed, 
the findings reflected in this study may not be generalizable to all 
psychiatrists and FM specialists. Our sample included only a very 
small group of physicians with specialized training in addictions. 
Therefore, it is not possible to compare their responses regard-
ing efficacy to those of physicians without specialized training. 
Previous studies in Veterans Health Administration facilities and 
specialized addiction treatment facilities, however, have noted 
that presence and availability of addictions-trained physicians 
increased the practice of pharmacotherapy in treatment of alco-
hol dependence (4, 7, 8).
When examining efficacy, our survey did not gather specific 
information about patient population, duration of treatment, or 
dosing. It is possible that physicians’ concerns about efficacy are 
related to their own understanding and expectations of efficacy 
of these medications for the treatment of AUDs. For example, 
in research trials, only relapse to heavy drinking was considered 
a true relapse in the analyses for the majority of medications 
promoting abstinence (naltrexone, acamprosate, and disul-
firam). Drinking “slips” and “lapses” were not counted when 
determining efficacy in maintaining abstinence, and therefore, 
providers and/or patients may have had different expectations. 
Often patients quickly abandon medications they believe are 
not efficacious and do not allow for the prolonged therapeutic 
trial, as is the case in research studies. Although abstinence is 
the desired goal for most treatment approaches, even reduction 
in drinking has shown to reduce negative consequences and 
improve quality of life.
“Efficacy” was not defined in our study, and physicians of dif-
ferent specialties and/or levels of training may have had different 
metrics for determining efficacy. This difference in clinical signifi-
cance is an important factor that has been found in other studies 
to matter even more to physicians than the demonstrated effect 
size of these medications (6, 16). Mark et al. found that physicians 
prescribed antidepressants to patients with alcohol dependence 
at a rate 3.5 times that of naltrexone, although they were able to 
correctly identify the effect size of antidepressants in treatment of 
depression as much smaller than that of naltrexone (6).
The survey assesses lifetime prescription of these medica-
tions, but not the proportion of patients with AUDs that these 
physicians treat. A physician with only a handful of patients with 
AUDs who are receiving pharmacotherapy may have a different 
perception than a physician with more experience in treating this 
population, which may affect perception of treatment response in 
some of the prescribers. A higher volume of patients with AUDs 
allows for more opportunities to use medications and experience 
success.
Among those physicians who have not used pharmaco-
therapy in the treatment of AUDs, with FM physicians being 
the majority, scant training was identified as the main problem 
impeding greater prescription. Similarly, physicians currently 
in training had lower prescription rates compared to senior 
physicians. Insufficient knowledge and clinical skills in the 
evaluation and management of SUDs among physicians in 
training can be exacerbated by negative attitudes toward this 
patient population (18).
A large proportion of physicians would welcome the 
opportunity of incorporating education in residency training 
programs on pharmacotherapy for AUDs. As in other surveys, 
some physicians selected increasing patient education about 
these medications as desirable, as it allows for a greater interest 
in trials of pharmacotherapy. Psychosocial treatment, includ-
ing 12-step programs, and pharmacotherapy are not mutually 
exclusive and can be used simultaneously for better results. 
The COMBINE study revealed that the use of medications 
like naltrexone and acamprosate in combination with medical 
counseling (non-specialized) can have clinically significant 
outcomes, highlighting that delivery of effective treatment can 
occur in health-care settings where specialized addiction treat-
ment is not available (19).
Determining the best predictors for treatment response 
should help alleviate some of the uncertainties reported with 
medications’ efficacy and would lead to a more individualized 
treatment approach. This would take into account pharmacoge-
netics, drinking patterns (11, 17), comorbidities, and treatment 
goals.
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